Scarica l'app Stockscreener
58.95
2.32%
-1.40
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Veeva and BioMarin form strategic partnership to accelerate therapies By Investing.com - Investing.com Nigeria
How BioMarin Pharmaceutical Inc. (BM8) stock compares with tech leaders2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - ulpravda.ru
Veeva and BioMarin Form Long-Term Strategic Partnership - Sahm
What RSI levels show for BioMarin Pharmaceutical Inc. (BM8) stockPortfolio Performance Summary & High Accuracy Investment Entry Signals - ulpravda.ru
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA - PR Newswire
Will BioMarin Pharmaceutical Inc. stock outperform Nasdaq indexIPO Watch & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
What catalysts could drive BioMarin Pharmaceutical Inc. stock higher2025 EndofYear Setup & Fast Exit and Entry Trade Guides - ulpravda.ru
Is BioMarin Pharmaceutical Inc. (BM8) stock a buy during volatile marketsPortfolio Risk Report & Free Community Consensus Stock Picks - ulpravda.ru
Veeva, BioMarin Enter Long-Term Strategic Partnership - Contract Pharma
Veeva Systems Expands Long-Term Partnership With BioMarin Pharmaceutical - Nasdaq
BioMarin fends off Kuvan generics competition again - The Pharma Letter
Published on: 2026-01-08 12:48:27 - ulpravda.ru
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
10 Magnificent Stocks That Can Make You Richer in 2026 - The Motley Fool
Taking a Fresh Look at BioMarin Pharmaceutical’s (BMRN) Valuation After Its Recent Share Price Rebound - Sahm
How Investors Are Reacting To BioMarin (BMRN) Halting BMN349 And Refocusing Its Rare Disease Pipeline - Yahoo Finance
19,329 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Financiere des Professionnels Fonds d investissement inc. - MarketBeat
Technical Analysis: What RSI levels show for BioMarin Pharmaceutical Inc BM8 stock2025 Market Trends & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Investor Mood: How BioMarin Pharmaceutical Inc stock performs in weak economyJuly 2025 Pullbacks & Safe Entry Trade Reports - moha.gov.vn
Blue Trust Inc. Sells 17,973 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? - Finviz
Cwm LLC Has $8.90 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioCentury’s 2025-26 picks and predictions. Plus: BioMarin and more biotech ICYMI — a BioCentury podcast - biocentury.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal - FinancialContent
BioMarin ends development of BMN 349 AATD therapy - MSN
BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma
Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio?Astera Labs (NASDAQ:ALAB), BioMarin Pharmaceutical (NASDAQ:BMRN), Ciena (NYSE:CIEN), CoreWeave (NA - Benzinga
Portfolio Update: How BioMarin Pharmaceutical Inc stock performs in weak economy2025 Earnings Impact & Long-Term Investment Growth Plans - moha.gov.vn
Rice Hall James & Associates LLC Boosts Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Pacer Advisors Inc. - MarketBeat
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - Seeking Alpha
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
Swedbank AB Buys 35,000 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin names new chief accounting officer - MSN
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
Silver Tops $70, Novo Nordisk Soars 9% On Obesity Pill ApprovalBullish (NYSE:BLSH), BioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga
BioMarin drops development of liver, lung disease asset - MSN
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion - New Jersey Business Magazine
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Finviz
What's Going On With BioMarin Stock On Tuesday? - Sahm
BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $100.00 Price Target at Truist Financial - MarketBeat
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition - Finviz
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio - Morningstar
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):